Peginterferon Alfa-2
ApprovedSmall molecule
RochePeginterferon Alfa-2 is one of 378 small molecule programs targeting Insulin resistance. It is currently in Approved.
12
Indications
177
Total Trials
0
Active Trials
377
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Peginterferon Alfa-2
RocheApproved
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
Keyhole-Limpet Hemocyanin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis104 trials
Show 101 more trials
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00475176·24 enrolled
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00028093·50 enrolled
High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
Completed·—·Phase 4·NCT00830609·101 enrolled
Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B
Completed·—··NCT01311947·103 enrolled
Hepatitis C22 trials
Show 19 more trials
Hepatitis C Antiviral Resistance in African-Americans
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00038974·401 enrolled
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
Completed·—·Phase 3·NCT00136318·208 enrolled
Treatment of Hepatitis C in Hemophilic Patients With HIV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00055341·22 enrolled
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00006164·1,050 enrolled
Efficacy and Safety6 trials
Treatment6 trials
Show 3 more trials
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02364336·14 enrolled
TED4 trials
23 more indications
Chronic Hepatitis C Virus Infection4 trials
Function3 trials
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
Unknown status·—·Phase 4·NCT03209037·100 enrolled
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
Unknown status·—·N/A·NCT03210493·120 enrolled
Hepatitis C Virus Infection3 trials
Hepatitis B2 trials
Efficacy2 trials
Fibrosis2 trials
Liver Disease1 trial
HCC1 trial
Cytokines1 trial
The Changes of Cytokines During Antiviral Therapy
Unknown status·—·N/A·NCT03210506·120 enrolled
HIE1 trial
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT01464281·300 enrolled
Natural Killer Cell1 trial
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
Unknown status·—·Phase 4·NCT03208998·100 enrolled
Tics1 trial
Safety and Efficacy1 trial
Liver Transplant1 trial
HCV Infection1 trial
Induction Therapy1 trial
Prospective1 trial
Liver Cancer1 trial
Chronic Myelogenous Leukemia1 trial
Insulin resistance1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peginterferon Alfa-2. EMBL-EBI & Wellcome Sanger Institute.
- [4]